Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(2.25) per share which missed the analyst consensus estimate of $(1.57) by 42.95 percent. This is a 65.44 percent decrease over losses of $(1.36) per share from the same period last year. The company reported quarterly sales of $1.936 million which missed the analyst consensus estimate of $3.556 million by 45.56 percent. This is a 318.14 percent increase over sales of $463.000 thousand the same period last year.